Business Context and Reporting Period
This Form 8-K was filed by Relmada Therapeutics, Inc. on June 12, 2017, reporting events occurring on June 12 and June 15, 2017. The filing addresses corporate governance changes and the entry into a material definitive agreement.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. The document focuses exclusively on executive compensation and contractual agreements.
Material Changes and Agreements
- Board Appointment: Effective June 15, 2017, Charles J. Casamento was appointed Chairman of the Board. He has served as a director since July 2015 and chairs the Audit Committee. He will receive additional compensation of $50,000 per year for this role.
- Consulting Agreement: On June 12, 2017, the Company entered into a one-year Consulting Agreement with director Maged Shenouda. Mr. Shenouda will be paid a consulting fee of $10,000 per month to assist with matters requested by the Company.
Guidance, Outlook, and Risks
The filing text does not provide a clear value for financial guidance, outlook, management commentary on operations, risks, contingencies, or unusual items. The document is limited to the disclosure of the specific agreements and appointments noted above.
Investor Verification Checklist
- Verify the total annual cost of the new Chairman compensation ($50,000) and the monthly consulting fee for Maged Shenouda ($10,000).
- Confirm the term of the Consulting Agreement with Maged Shenouda (one year).
- Review the full text of the Consulting Agreement, which is noted to be included as an exhibit to the Form 10-K for the year ending June 30, 2017.
- Check subsequent filings for any updates to the Board composition or additional compensation arrangements.